The human promoter was used to drive ubiquitous expression of the C-terminal portion of human APP (C100) with an amino acid substitution of phenyalanine for valine at position 717 (V717F), also known as the London mutation. One line was created (no line number given) with 40 to 50 copies of the transgene.